Ildong Pharmaceutical announced in a disclosure on the 30th that its provisional operating profit for the second quarter of this year, on a consolidated basis, recorded 5 billion won, a 739.1% increase compared to the same period last year.


During the same period, sales reached 150.9 billion won, up 9%, and net profit for the period was 8.1 billion won, turning profitable from a net loss of 3.9 billion won in the same period last year.


Panoramic view of Ildong Pharmaceutical Group headquarters in Seocho-gu, Seoul. Ildong Pharmaceutical

Panoramic view of Ildong Pharmaceutical Group headquarters in Seocho-gu, Seoul. Ildong Pharmaceutical

View original image

On a cumulative basis for the first half of the year, sales amounted to 292.9 billion won and operating profit was 14.2 billion won, up 6.7% and 197%, respectively, compared to the same period last year. Cumulative net profit for the first half also turned positive, posting 15.5 billion won.


The main drivers behind this performance improvement are cited as balanced growth in both the prescription drug (ETC) and over-the-counter (OTC) businesses. In the prescription drug segment, new sales contributions came from co-promotion items in the urological category, while in the OTC segment, robust sales of core brands, including smaller patch products, led to overall expansion in business scale.



In addition, overall profitability indicators have significantly improved due to successful management efficiency initiatives, such as increased productivity and reduced cost of goods sold.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing